$ cat ./records/gates-foundation-funds-phase-i-safety-trial-of-anti-tick-vaccine--2021.txt
Gates Foundation Funds Phase I Safety Trial of Anti-Tick Vaccine Targeting Tick Cement Proteins to Block Lyme Transmission
[RECORD.TXT] · cat --full
Building on mRNA tick-vaccine research at Yale University funded in prior years, the Gates Foundation supported a Phase I clinical safety trial of a vaccine targeting cement proteins that Ixodes scapularis ticks secrete to anchor themselves during feeding. Disrupting tick attachment prevents the prolonged feeding required to transmit Borrelia burgdorferi (Lyme disease). The trial enrolled healthy volunteers and demonstrated the vaccine to be safe and immunogenic, advancing the platform toward larger efficacy trials.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Land Report Names Bill Gates the Largest Private Farmland Owner in the United States with Over 269,000 Acres Across 18 States
Next →
Gates Foundation Awards $1.28 Million to Oxitec to Develop Self-Limiting Cattle Tick Biocontrol
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.